Once the clinical trials are successfully completed in India, Biosergen and Alkem aim to expand its use for similar patient groups in the US and EU via pivotal trials.

Making "M" pattern in 30 Min time frame#ALKEM ✌️✌️Intraday Stock for Tomorrow 18.09.23

Gupta holds an M.B.B.S degree from University College of Medical Sciences, Delhi University and has over to decades of experience in pharmaceutical sector

The company added that this action has has no impact on the operations of the company.

The achievement of surpassing the 20-day SMA is a notable technical milestone for these midcap stocks, often indicating short-term positive trends.

 Alkem recalled 99,516 sachets of antibiotic used to treat bladder infections and Caplin recalled 19,820 vials of heart medication according to US FDA Enforcement Report

Limitless potential for future global advancements in gene therapies is originating from India, said Dr David Gamm.

Motilal Oswal recommended Neutral rating on Alkem Laboratories with a target price of Rs 3810 in its research report dated August 10, 2023.

The data was sourced from BSE at 2.50 pm, and the updates from the real-time data could come with a lag. The below data also pertains only to the time at which it was taken.

August 3 witnessed a remarkable surge in the BSE MidCap segment as several stocks hit new 52-week highs, displaying strong bullish momentum despite market fluctuations.

Trade generics are branded medicines that are not promoted to physicians but are directly sold through retailers and distributors. In India, trade generics have a market share of 20% by volume and 5-6% by value, according to data and analytics firm IQVIA. The segment is growing around 14-15% per annum.

RSI is a technical indicator that measures the magnitude of recent price changes in a stock to evaluate its overbought or oversold status. Ranging from 0 to 100, RSI above 70 indicates overbought conditions, while RSI below 30 indicates oversold conditions

On July 25, Tuesday, StockEdge reported a staggering number of 90 stocks trading in the overbought zone, indicating potential cautionary signals for investors

The veteran market investor follows a bottom up approach and likes the sector due to its diverse nature.

Net Sales are expected to increase by 10.5 percent Y-o-Y (up 1.9 percent Q-o-Q) to Rs 2,847.5 crore, according to Nirmal Bang.

The nationwide launch of the company's ophthalmology product range ensures that patients across India have access to quality eye-care formulations at an affordable price, the company said in a statement.